SEC 13F Intelligence

Managers / Q1 2021 · view latest →

Altium Capital Management LLC

CIK 0001746382 · 152 W 57 ST FL7, NEW YORK, NY, 10019 · 2124842711

Reported Value
$360M
Q1 2021
Positions
124
Filings on Record
25
2019–present window
Filed
May 6, 2021
original filing

Summary

Altium Capital Management LLC reported $360M in U.S.-listed holdings across 124 positions for Q1 2021.

Its largest position, Curis, represents 2.4% of the portfolio.

Compared with Q4 2020, the fund opened 61 new positions and exited 31.

Portfolio Metrics

Turnover
+32.7%
vs prior filed quarter
Top-10 Concentration
+19.8%
share of reported value
Largest Position
+2.4%
Curis
New / Exited
61 / 31
positions this quarter

Methodology: turnover is min(value bought, value sold) ÷ average reported value across the two quarters — value-based, so market moves inflate it slightly versus a share-based measure. Concentration and largest position are shares of the filing’s total reported value, options excluded, with multiple share classes and repeated sub-manager rows for the same issuer combined into one position — the same rule the holdings table uses by default. New/exited counts compare against the prior filed quarter. All figures derive solely from the fund’s 13F filings.

Reported Value by Quarter

13F Reported Value
Q4 ’20: $268MQ4 ’20Q1 ’21: $360MQ2 ’21: $431MQ3 ’21: $381MQ3 ’21Q4 ’21: $363MQ1 ’22: $299MQ2 ’22: $250MQ2 ’22Q3 ’22: $273MQ4 ’22: $197MQ1 ’23: $180MQ1 ’23Q2 ’23: $132MQ3 ’23: $192MQ4 ’23: $147MQ4 ’23Q1 ’24: $253MQ2 ’24: $245MQ3 ’24: $340MQ3 ’24Q4 ’24: $353MQ1 ’25: $42MQ2 ’25: $0Q2 ’25Q3 ’25: $628,262Q4 ’25: $25MQ1 ’26: $42MQ1 ’26filingsflow.com

Portfolio Composition

By security type
Common Stock: 60.6%Other: 37.3%ADR: 1.7%Equity WRT: 0.4%
  • Common Stock · 60.6% · $218M
  • Other · 37.3% · $134M
  • ADR · 1.7% · $6M
  • Equity WRT · 0.4% · $2M

Quarter-over-Quarter Changes full breakdown →

vs Q4 2020 (amended baseline)

IssuerMoveShare ΔShares nowValue ΔValue now
PROGENITY INCNEW+1.75M1.75M+$8M$8M
ALDXALDEYRA THERAPEUTICS INCNEW+548.2K548.2K+$7M$7M
CDNACAREDX INCNEW+81.3K81.3K+$6M$6M
NEVRO CORPNEW+37.9K37.9K+$5M$5M
NOCTURNE ACQUISITION CORPNEW+500.0K500.0K+$5M$5M
CELSION CORPNEW+3.50M3.50M+$5M$5M
RYTMRHYTHM PHARMACEUTICALS INCNEW+223.0K223.0K+$5M$5M
FORTE BIOSCIENCES INCNEW+134.5K134.5K+$5M$5M

Value changes conflate price moves with buying and selling — share changes are the real signal. Share counts are not split-adjusted.

Holdings — Q1 2021

121 positions
Export to Excel
#IssuerClass% PortfolioValue ↓Shares
1CURIS INCCOM NEW2.43%$9M772.0K
2VERRICA PHARMACEUTICALS INCCOM2.37%$9M563.0K
3PROGENITY INCCOM2.31%$8M1.75M
4CHARDAN HEALTHCR ACQSTN 2 COCOM · *W EXP 03/05/2022.29%$8M1.48M
5ESSA PHARMA INCCOM NEW1.86%$7M230.1K
6ALDXALDEYRA THERAPEUTICS INChistory →COM1.81%$7M548.2K
7VERASTEM INCCOM1.76%$6M2.57M
8PTGXPROTAGONIST THERAPEUTICS INChistory →COM1.71%$6M238.4K
9BLUBELLUS HEALTH INC NEWhistory →COM NEW1.68%$6M1.57M
10LNTHLANTHEUS HLDGS INChistory →COM1.63%$6M275.1K
11SNDXSYNDAX PHARMACEUTICALS INChistory →COM1.57%$6M253.4K
12IVERIC BIO INCCOM1.55%$6M902.6K
13CDNACAREDX INChistory →COM1.54%$6M81.3K
14CRNXCRINETICS PHARMACEUTICALS INhistory →COM1.54%$6M361.9K
15PODDINSULET CORPhistory →COM1.52%$5M21.0K
16SIENTRA INCCOM1.50%$5M739.0K
17OCULOCULAR THERAPEUTIX INChistory →COM1.47%$5M326.2K
18AUPHAURINIA PHARMACEUTICALS INChistory →COM1.47%$5M408.9K
19NEVRO CORPCOM1.47%$5M37.9K
20TVTXTRAVERE THERAPEUTICS INChistory →COM1.46%$5M210.5K
21MYGNMYRIAD GENETICS INChistory →COM1.45%$5M171.8K
22SUTRO BIOPHARMA INCCOM1.43%$5M226.7K
23NOCTURNE ACQUISITION CORPUNIT 02/25/20261.39%$5M500.0K
24CELSION CORPCOM PAR NEW1.34%$5M3.50M
25RYTMRHYTHM PHARMACEUTICALS INChistory →COM1.32%$5M223.0K
26TCR2 THERAPEUTICS INCCOM1.28%$5M209.1K
27FORTE BIOSCIENCES INCCOM1.28%$5M134.5K
28MREOMEREO BIOPHARMA GROUP PLChistory →ADS1.17%$4M1.25M
29HARPOON THERAPEUTICS INCCOM1.16%$4M199.6K
30IMMATICS N.VSHS · *W EXP 07/01/2021.15%$4M442.0K
31EUCRATES BIOMEDICAL ACQU CORUNIT 10/23/20271.11%$4M400.0K
32AVADEL PHARMACEUTICALS PLCSPONSORED ADR1.11%$4M440.6K
33ARYA SCIENCES ACQUISITION COCOM CL A1.10%$4M286.4K
34AVIDITY BIOSCIENCES INCCOM1.08%$4M178.6K
35INSMINSMED INChistory →COM PAR $.011.04%$4M110.3K
36CTMXCYTOMX THERAPEUTICS INChistory →COM1.04%$4M483.0K
37CNSTCONSTELLATION PHARMCETICLS Ihistory →COM1.03%$4M158.7K
38IMVTIMMUNOVANT INChistory →COM1.02%$4M229.6K
39TFF PHARMACEUTICALS INCCOM1.02%$4M269.7K
40ALPHA HEALTHCARE ACQUISTN COUNIT 09/21/20270.95%$3M275.0K
41NEWAGE INCCOM0.95%$3M1.20M
42GKOSGLAUKOS CORPCOM0.95%$3M40.8K
43ARQTARCUTIS BIOTHERAPEUTICS INCCOM0.92%$3M114.0K
44KALVISTA PHARMACEUTICALS INCCOM0.91%$3M128.1K
45CHINOOK THERAPEUTICS INCCOM0.89%$3M205.8K
46INFIQINFINITY PHARMACEUTICALS INCCOM0.87%$3M972.3K
47ILMNILLUMINA INCCOM0.85%$3M8.0K
48INFLARX NVCOM0.84%$3M774.6K
49GMEDGLOBUS MED INCCL A0.84%$3M48.9K
50INTRA CELLULAR THERAPIES INCCOM0.83%$3M88.3K
51INTERSECT ENT INCCOM0.82%$3M141.9K
52MORPHIC HLDG INCCOM0.82%$3M46.5K
53EYPTEYEPOINT PHARMACEUTICALS INCCOM NEW0.82%$3M289.3K
54NUVASIVE INCCOM0.79%$3M43.1K
55GEMINI THERAPEUTICS INCCOM0.77%$3M204.0K
56PHASEBIO PHARMACEUTICALS INCCOM0.74%$3M775.0K
57DYNDYNE THERAPEUTICS INCCOM0.72%$3M166.6K
58CFMSCONFORMIS INCCOM0.72%$3M2.61M
59HELIX ACQUISITION CORPCOM CL A0.71%$3M250.0K
60PROFPROFOUND MED CORPCOM NEW0.71%$3M126.4K
61TURMERIC ACQUISITION CORPUNIT 10/08/20250.71%$3M254.0K
62LIFESCI ACQUISITION II CORPCOM0.70%$3M250.0K
63CONSONANCE HFW ACQUISITION CUNIT 99/99/99990.68%$2M250.0K
64SARISSA CAPITAL ACQUISITN COUNIT 10/23/20270.68%$2M225.0K
65CYTKCYTOKINETICS INCCOM NEW0.67%$2M103.3K
66IRDOCUPHIRE PHARMA INC #COM0.64%$2M397.0K
67WVEWAVE LIFE SCIENCES LTDSHS0.62%$2M399.0K
68MEI PHARMA INCCOM NEW0.61%$2M638.1K
69VREXVAREX IMAGING CORPCOM0.60%$2M105.7K
70ADAMAS PHARMACEUTICALS INCCOM0.60%$2M450.0K
71SERES THERAPEUTICS INCCOM0.60%$2M104.6K
72AEGLEA BIOTHERAPEUTICS INCCOM0.59%$2M267.8K
73PYXIS TANKERS INCCOM0.58%$2M2.04M
74CALITHERA BIOSCIENCES INCCOM0.57%$2M853.9K
75HEALTHCOR CATALIO ACQU CORPCL A SHS0.56%$2M200.0K
76CHRSCOHERUS BIOSCIENCES INCCOM0.55%$2M136.6K
77FS DEVELOPMENT CORP IICOM CL A0.55%$2M200.0K
78JIYA ACQUISITION CORPCOM CL A0.55%$2M200.0K
79YUMANITY THERAPEUTICS INCCOM0.55%$2M108.7K
80MAGENTA THERAPEUTICS INCCOM0.54%$2M164.4K
81LANDCADIA HOLDINGS III INCCOM CL A0.53%$2M192.3K
82HAEHAEMONETICS CORP MASSCOM0.53%$2M17.0K
83ACE CONVERGENCE ACQU CORPCL A0.52%$2M189.0K
84CSTLCASTLE BIOSCIENCES INCCOM0.52%$2M27.4K
85ADICET BIO INCCOM0.52%$2M142.3K
86SALARIUS PHARMACEUTICALS INCCOM NEW0.51%$2M1.25M
87CM LIFE SCIENCES INCCOM CL A · *W EXP 09/04/2020.51%$2M166.7K
88EIGER BIOPHARMACEUTICALS INCCOM0.49%$2M197.5K
89CTI BIOPHARMA CORPCOM0.48%$2M589.0K
90STIMNEURONETICS INCCOM0.47%$2M137.5K
91BWAYBRAINSWAY LTDSPONSORED ADS0.45%$2M179.5K
92XGNEXAGEN INCCOM0.42%$2M86.5K
93ONCTERNAL THERAPEUTICS INCCOM0.41%$1M176.3K
94VALLON PHARMACEUTICALS INCCOM0.39%$1M300.0K
95LRMRLARIMAR THERAPEUTICS INCCOM0.38%$1M93.3K
96BCTG ACQUISITION CORPCOM0.37%$1M120.0K
97TAILWIND ACQUISITION CORPCOM CL A0.35%$1M128.4K
98VRAYQVIEWRAY INCCOM0.35%$1M289.1K
99GIGCAPITAL4 INCUNIT 99/99/99990.34%$1M125.0K
100BCLS ACQUISITION CORPCOM CL A0.29%$1M100.0K

Filing History

QuarterReported ValuePositionsFiledTypeLinks
Q1 2026$42M19May 1, 202613F-HRchanges · EDGAR ↗
Q4 2025$25M18Feb 6, 202613F-HRchanges · EDGAR ↗
Q3 2025$628,2621Nov 4, 202513F-HRchanges · EDGAR ↗
Q2 2025$01Aug 7, 202513F-HRchanges · EDGAR ↗
Q1 2025$42M24May 13, 2025RESTATEMENTchanges · EDGAR ↗
Q4 2024$353M67Feb 13, 202513F-HRchanges · EDGAR ↗
Q3 2024$340M79Nov 14, 202413F-HRchanges · EDGAR ↗
Q2 2024$245M68Aug 15, 202413F-HRchanges · EDGAR ↗
Q1 2024$253M72May 15, 202413F-HRchanges · EDGAR ↗
Q4 2023$147M66Feb 14, 202413F-HRchanges · EDGAR ↗
Q3 2023$192M72Nov 14, 202313F-HRchanges · EDGAR ↗
Q2 2023$132M68Aug 14, 202313F-HRchanges · EDGAR ↗
Q1 2023$180M91May 15, 202313F-HRchanges · EDGAR ↗
Q4 2022$197M94Feb 14, 202313F-HRchanges · EDGAR ↗
Q3 2022$273M134Nov 14, 202213F-HRchanges · EDGAR ↗
Q2 2022$250M127Aug 15, 202213F-HRchanges · EDGAR ↗
Q1 2022$299M118May 16, 202213F-HRchanges · EDGAR ↗
Q4 2021$363M133Feb 14, 202213F-HRchanges · EDGAR ↗
Q3 2021$381M124Nov 17, 2021RESTATEMENTchanges · EDGAR ↗
Q2 2021$431M135Aug 13, 202113F-HRchanges · EDGAR ↗
Q1 2021$360M124May 6, 202113F-HRchanges · EDGAR ↗
Q4 2020$268M95May 5, 2021RESTATEMENTchanges · EDGAR ↗

13F filings are due up to 45 days after quarter end, so holdings shown here lag the fund’s current book. Source: original SEC filing on EDGAR ↗.